Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights
Stock Information for Jounce Therapeutics Inc.
Please wait while we load your information from QuoteMedia.
More Recent News About Jounce Therapeutics Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Jounce Therapeutics, Inc. (Nasdaq- JNCE) and Berkshire Grey, Inc. (Nasdaq- BGRY)
JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders